Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression (PSILODAC)

This interventional trial (n=12) will investigate the effect of a single 25 mg dose of psilocybin on the positive valence system in patients with treatment-resistant depression (TRD).

The study, conducted by the Centre Hospitalier Universitaire de Nîmes, aims to explore whether psilocybin reduces anhedonia and increases motivation by enhancing reward anticipation.

Functional MRI scans will measure brain activity before and after psilocybin administration, focusing on key neural circuits involved in effort evaluation and reward processing. The trial will assess correlations between brain activity changes and depression severity, behavioural activation, and anhedonia scores. Findings will contribute to understanding psilocybin’s antidepressant mechanisms and its feasibility for use in a French clinical population.

Topic Depression Treatment-Resistant Depression Neuroscience
Compound Psilocybin
Country France
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.